U.S. markets closed

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4450-0.0350 (-7.29%)
At close: 04:00PM EDT
0.4700 +0.03 (+5.62%)
After hours: 07:44PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close0.4800
Bid0.4413 x 900
Ask0.4700 x 1100
Day's Range0.4400 - 0.4780
52 Week Range0.3900 - 2.1600
Avg. Volume4,210,557
Market Cap14.494M
Beta (5Y Monthly)0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.9610
Earnings DateOct 19, 2022 - Oct 24, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PSTV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    VCEL: What does Argus have to say about VCEL?VERICEL CORP has an Investment Rating of SELL; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Benzinga

    Why Are Plus Therapeutics Shares Gaining Today?

    Plus Therapeutics Inc (NASDAQ: PSTV) has finalized and signed a grant contract with the Cancer Prevention & Research Institute of Texas (CPRIT) for its previously announced $17.6 million Product Development Research funding award. The award will cover most of the development costs of the company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for leptomeningeal metastases (LM) over three years, beginning in the fourth quarter of 2022. Related: Plus Therapeuti

  • GlobeNewswire

    Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas

    Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support majority of 186RNL targeted therapeutic development costs for leptomeningeal metastases program over three years; extends expected Company cash runway through 2025 AUSTIN, Texas, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-tr

  • GlobeNewswire

    Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

    Phase 1 data indicates that direct administration of 186RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma Statistically significant overall survival benefit observed with 186RNL radiation doses over 100 Gray NIH-funded trial moving to Phase 2 to explore expanded dosing parameters, treat larger tumor sizes, and gather additional safety and efficacy data, that will support a future registrational trial AUSTIN, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics,